ClinicalTrials.gg
RecruitingNCT05047094Updated Apr 6, 2026

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

An interventional study of Diffusing Alpha Radiation Emitters Therapy (DaRT) and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, Skin Cancer and Metastatic Head-and-neck Squamous-cell Carcinoma, sponsored by Alpha Tau Medical LTD.. Recruiting at 3 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Alpha Tau Medical LTD. · Not applicable, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Squamous Cell Carcinoma of Head and Neck with a site in Israel — 13 open to participants now, 22 under way, 7 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Israel.

Planned enrollment
34th of 45
48 · median 248
Started
2021
with 8 others
No phase
7 of 46
4 open now
Primary completion
2026-12
later than 5 of 21 live
Registered
33rd of 46
by date
Lead sponsor
7 of 46
Alpha Tau Medical LTD.

Among the 46 studies in Squamous Cell Carcinoma of Head and Neck with a site in Israel, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2021, is one of 7 with no phase, reaches primary completion later than 5 of the 21 other live ones, and was the 33rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

13 of the 46 studies in Squamous Cell Carcinoma of Head and Neck with a site in Israel are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Squamous Cell Carcinoma of Head and Neck with a site in Israel, or all of them as a file.
02

Study summary

A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma

Read the detailed description

This will be a prospective, open-label, one arm, single center two-stage adaptive trial designed to stop for either futility or efficacy after the first stage.

This approach will combine Diffusing Alpha Radiation Emitters seeds implantation along with standard treatment of Pembrolizumab for patients with recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma (mHNSCC).

The DaRT seeds will be implanted in the target lesion and removed 15-22 days after implantation. Concurrently, patient will receive standard treatment of Pembrolizumab.

Disease evaluation will be assessed by a radiological imaging every 6 weeks starting at day 42 after the DaRT insertion procedure.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Skin Cancer
  • Metastatic Head-and-neck Squamous-cell Carcinoma

Keywords

  • Squamous Cell Carcinoma
  • SCC
  • Skin Cancer
  • Skin metastasis
  • HNSCC
  • Carcinoma, Squamous
  • Recurrent disease
  • Alpha radiation
  • Brachytherapy
  • Pembrolizumab
  • Check Point Inhibitor
  • KEYTRUDA
  • Immunomodulators
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed, , or recurrent unresectable squamous cell carcinoma of the head and neck.
  2. Ability to provide tissue sample, either from an archive or undergo another to provide a fresh sample
  3. Targetable lesion must be technically amenable for the DaRT seeds implantation
  4. Brachytherapy indication validated by a multidisciplinary team
  5. Targetable lesion according to v1.1
  6. Age ≥ 18 years old
  7. (ECOG) Performance Status Scale ≤ 2
  8. Subjects' is more than 6 months
  9. White Blood Count (WBC) ≥ 3500/µl, granulocyte ≥ 1500/µl
  10. count ≥ 100,000/µl
  11. ≥ 9 g/dl
  12. Calculated or measured ≥ 60 cc/min
  13. (AST) and Alanine Transaminase (ALT) ≤ 2.5 X (ULN) or ≤ 5 X ULN for subjects with liver metastases
  14. (INR) \<1.4 for patients not on Warfarin
  15. Subjects are willing and able to sign an form
  16. Women of (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable method to prevent pregnancy for 3 months after brachytherapy.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment for disease (for recurrent unresectable disease, previous treatment is allowed given that 6 months had elapsed from completion of treatment for primary disease)
  2. Patients with
  3. Combined Positive Scores (CPS) \<1
  4. Patients with known to radiotherapy
  5. Any prior therapy with (Programmed death-ligand), anti-PD-L2, anti-CTLA-4 (Cytotoxic T lymphocyte antigen) antibody, etc.
  6. Any history of a sever reaction to any monoclonal antibody.
  7. Known hypersensitivity to any of the components of the DaRT.
  8. Has a known history of active TB (Tuberculosis Bacillus )
  9. Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  10. Any diagnosis of immunodeficiency or current therapy including >10mg/day of prednisone within 14 days of enrollment is not permitted
  11. cardiovascular disease, e.g. cardiac failure of classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
  12. Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
  13. Patient requires treatment which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
  14. Has a known history of (HIV) (HIV 1/2 antibodies).
  15. Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected)
  16. Pregnancy or lactation.
  17. Patients must agree to use adequate (abstinence, barrier method of birth control, or any other medically acceptable form of contraception) prior to study entry, for the duration of study participation and for 6 months after last dose of Pembrolizumab.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    DaRT seeds

    Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds in Combination with Standard Treatment of Pembrolizumab

    Device: Diffusing Alpha Radiation Emitters Therapy (DaRT) · Drug: Pembrolizumab

Interventions

  • DeviceDiffusing Alpha Radiation Emitters Therapy (DaRT)

    An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

    Also known as: DaRT

  • 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks

    Also known as: KEYTRUDA

06

What researchers measure

Primary outcomes

  1. Evaluation of Efficacy of DaRT Treatment in Combination with Pembrolizumab

    Assessed via the Confirmed Best Overall Response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)

    Time frame: From Day 26 to date of documented best response, assessed up to 24 months

Secondary outcomes

  1. Adverse Events

    Assessment of the frequency, severity and causality of acute adverse events related to the DaRT treatment in combination with immune checkpoint inhibitors. This will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0. (graded 1-5, 1 is mild and 5 is death)

    Time frame: Until completion of the last study-related procedure, approximately 2 years

  2. Progression Free Survival (PFS)

    PFS will be defined as time from Pembrolizumab treatment start date to progressive disease according to RECIST v1.1 or death due to any cause, whichever occurs first

    Time frame: From first dose of Pembrolizumab until progressive disease is recorded (up to 24 months)

  3. Overall Survival (OS)

    Defined as the time from Pembrolizumab treatment start date to death due to any cause or lost to follow up.

    Time frame: From Pembrolizumab treatment start date to death or lost to follow-up (up to 24 months)

  4. Duration of Response (DOR)

    Duration of response is defined as the interval from the time measurement criteria are first met for Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (whichever is first recorded) until the first date recurrent or progressive disease is objectively documented.

    Time frame: From first record of response until the first date recurrent or progressive disease is documented (up to 24 months)

Other outcomes

  1. Change in Expression of Immune-Related Biomarkers

    This study will assess the change in immune related biomarkers in peripheral blood using Fluorescence-activated cell sorting (FACS) analysis. These biomarkers include: CD3, CD4, CD8, CD69, CD137

    Time frame: On Day -16, day 0, day 15, and day 68

07

Study locations

2 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

Of 127 interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 61 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2021
First posted
Sep 16, 2021
StartActual
Nov 2, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05047094
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Nov 2, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Tami Granot
Contact
TamiG@alphatau.com
+972-2-3737-212
Liron Dimnik
Contact
LironD@alphatau.com
+972-2-3737-210
Aron Popovtzer, MD
principal investigator · Sharett institute, Hadassah Medical Center - Ein-Kerem

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion